We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.19 | 4.03% | 4.90 | 4.77 | 5.00 | 4.94 | 4.6895 | 4.84 | 4,668,267 | 05:00:08 |
Corporate Highlights
Fourth Quarter and Subsequent Achievements:
RSV
Influenza
Ebola
2015 Anticipated Events:
"We have initiated five clinical trials within the last six months, including advancing both our RSV and seasonal influenza programs into Phase 2 clinical trials, while introducing our new Ebola vaccine into the clinic," said Stanley C. Erck, President and Chief Executive Officer of Novavax. "These achievements underscore the strength of our vaccine technology, capability of our manufacturing platform and experience of our leadership team. We look forward to carrying this momentum through 2015, with important clinical data readouts expected in our RSV, seasonal influenza and Ebola programs."
Financial Results for the Three and Twelve Months Ended December 31, 2014
Novavax reported a net loss of $31.5 million, or $0.13 per share, for the fourth quarter of 2014, compared to a net loss of $14.1 million, or $0.07 per share, for the fourth quarter of 2013. For the twelve months ended December 31, 2014, the net loss was $82.9 million, or $0.37 per share, compared to a net loss of $52.0 million, or $0.31 per share for 2013.
Novavax revenue in the fourth quarter of 2014 decreased 23% to $6.7 million, compared to $8.7 million for the same period in 2013. Revenue for the full year 2014 increased 47% to $30.7 million, compared to $20.9 million in 2013. The increase in the full year revenue results from the Phase 1/2 clinical trial of our H7N9 pandemic influenza vaccine candidate with Matrix-M and activities relating to the preparation and initiation of the Phase 2 clinical trial of our Seasonal Influenza VLP; both programs are funded under our contract with HHS BARDA.
The cost of government contracts revenue in the fourth quarter of 2014 increased 9% to $2.8 million, compared to $2.6 million for the same period in 2013. For the full year 2014, cost of government contracts revenue increased 82% to $15.0 million, compared to $8.2 million in 2013. The increase in costs for the full year 2014 were associated with the Phase 1/2 clinical trial of our H7N9 pandemic influenza candidate with Matrix-M adjuvant and activities relating to the preparation and initiation of the Phase 2 clinical trial of our Seasonal Influenza VLP; both programs are funded under our contract with HHS BARDA.
Research and development expenses increased 87% to $30.5 million in the fourth quarter of 2014, compared to $16.3 million for the same period in 2013. For the full year 2014, research and development expenses increased 58% to $79.4 million, compared to $50.3 million in 2013. The increase in research and development expenses for the full year 2014 is driven by activities relating to the preparation and initiation of three RSV F Vaccine candidate clinical trials in 2014, the initiation of our Ebola vaccine candidate program and higher employee-related expenses tied to the continued growth of the company.
General and administrative expenses increased 24% to $5.1 million in the fourth quarter of 2014, compared to $4.1 million for the same period in 2013. For the full year 2014, general and administrative expenses increased 34% to $19.9 million, compared to $14.8 million in 2013. The increase in general and administrative expenses for the full year 2014 resulted from increased employee-related expenses tied to the continued growth of the company.
As of December 31, 2014, the company had $168.1 million in cash and cash equivalents and marketable securities compared to $133.1 million as of December 31, 2013. Net cash used in operating activities for 2014 was $67.0 million, compared to $45.4 million for 2013. The factors contributing to the change in cash usage were primarily due to increased costs relating to our RSV F Vaccine candidate and higher employee-related costs, as well as the timing of vendor payments.
Conference Call
Novavax management will host its quarterly conference call today at 4:30 p.m. EDT. The dial-in number for the conference call is 877-212-6076 (U.S. or Canada) or 707-287–9331 (International). A webcast of the conference call can also be accessed via a link on the home page of the Novavax website (novavax.com) or through the "Investor Info"/"Events" tab on the Novavax website.
A replay of the conference call will be available starting at 7:30 p.m. on February 26, 2015 until midnight March 5, 2015. To access the replay by telephone, dial 855-859-2056 (Domestic) or 404-537-3406 (International) and use passcode 89629680. The replay will also be available as a webcast and can be found on the "Investor Info"/"Events" on the Novavax website.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.
Forward-Looking Statements
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2014, to be filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
NOVAVAX, INC. | ||||
CONDENSED STATEMENTS OF OPERATIONS | ||||
(in thousands, except per share information) | ||||
Three Months Ended | Twelve Months Ended | |||
December 31, | December 31, | |||
2014 | 2013 | 2014 | 2013 | |
(unaudited) | ||||
Revenue | $ 6,724 | $ 8,748 | $ 30,659 | $ 20,915 |
Costs and expenses: | ||||
Cost of government contracts revenue | 2,837 | 2,602 | 14,987 | 8,222 |
Research and development | 30,495 | 16,319 | 79,435 | 50,308 |
General and administrative | 5,056 | 4,080 | 19,928 | 14,819 |
Total costs and expenses | 38,388 | 23,001 | 114,350 | 73,349 |
Loss from operations | (31,664) | (14,253) | (83,691) | (52,434) |
Interest income (expense), net | 118 | 10 | 129 | 27 |
Other income, net | ― | 192 | ― | 182 |
Realized gains on marketable securities | ― | ― | 615 | ― |
Change in fair value of warrant liability | ― | ― | ― | 267 |
Loss from operations before income tax expense | (31,546) | (14,051) | (82,947) | (51,958) |
Income tax expense | ― | 3 | ― | 25 |
Net loss | $ (31,546) | $ (14,054) | $ (82,947) | $ (51,983) |
Basic and diluted net loss per share | $ (0.13) | $ (0.07) | $ (0.37) | $ (0.31) |
Basic and diluted weighted average number of common shares outstanding | 238,519 | 208,538 | 225,848 | 169,658 |
SELECTED BALANCE SHEET DATA | ||
(in thousands) | ||
December 31, | December 31, | |
2014 | 2013 | |
Cash and cash equivalents | $ 32,335 | $ 119,471 |
Marketable securities | 135,721 | 13,597 |
Total current assets | 188,158 | 145,001 |
Working capital | 154,042 | 126,879 |
Total assets | 276,002 | 235,125 |
Total notes payable and capital lease obligations | 1,173 | 2,184 |
Total stockholders' equity | 229,618 | 203,234 |
CONTACT: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions